LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models

Authors: Rina Baba, Satoru Matsuda, Yuuichi Arakawa, Ryuji Yamada, Noriko Suzuki, Tatsuya Ando, Hideyuki Oki, Shigeru Igaki, Masaki Daini, Yasushi Hattori, Shigemitsu Matsumoto, Mitsuhiro Ito, Atsushi Nakatani, Haruhide Kimura

Published: 2021-03-12

DOI: 10.1126/sciadv.aba1187

Source: Full article

---

Abstract

LSD1 inhibitor TAK-418 could be a therapeutic option for neurodevelopmental disorders via normalization of gene expression.